Sorafenib after locoregional treatments for advanced or recurrent hepatocellular carcinoma

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter C. Ribeiro
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors C. Ribeiro1, J. Barreira2, A. Parmanande1, P. Semedo1, M. Semedo1, M. Silva1, N. Costa1, V. Ribeiro1, E. Coimbra1, E. Barroso1
  • 1CHLC, Lisboa, Portugal, /
  • 2CHLC, Lisbon, Portugal, /

Abstract

Patients with advanced hepatocellular carcinoma (HCC) have a dismal prognosis and few therapeutic options to improve survival. For the first time, in 2008, the SHARP study showed a survival benefit for these patients with a systemic treatment - Sorafenib, therefore changing clinical practice. Our aim was to determine whether previous locoregional treatments influenced exposure and response to Sorafenib.